High-resolution 3D image showing how the 5-HT1A receptor connects with internal signaling proteins (G proteins). The highlighted areas reveal key contact points between the receptor and two different ...

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing ...

Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to ...

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

DENVER - Aytu BioPharma, Inc. (NASDAQ:AYTU) announced Tuesday the nationwide commercial launch of EXXUA, the first FDA-approved selective 5-HT1A agonist for treating major depressive disorder (MDD) in ...

In a discovery that could guide the development of next-generation antidepressants and antipsychotic medications, researchers at the Icahn School of Medicine at Mount Sinai have developed new insights ...

Mount Sinai researchers took detailed pictures of the serotonin receptor and clinically-validated drug target 5-HT1A using cryo-electron microscopy to show how the psychedelics LSD and 5-MeO-DMT and a ...

LSD and 5-MeO-DMT, a psychedelic found in the secretions of the Colorado River Toad, are known to mediate their hallucinogenic effects through the serotonin receptor 5-HT2A, though these drugs also ...